The 2027 Immunology ST3 Interview Revision Platform: Question Bank, Live Practice and Mocks with Other Candidates

I'd like to present the OUtMATCH trial, by Wood and colleagues, published in the New England Journal of Medicine in 2024. It asked whether omalizumab, an anti-IgE monoclonal antibody, increases the amount of food that people with multiple food allergies can tolerate.

I chose it because it speaks to a gap I see in clinic every week. Most of my food-allergic patients manage by strict avoidance and an adrenaline auto-injector, and until recently there was nothing I could offer that reduced the consequences of an accidental exposure. Oral immunotherapy helps some of them, but it works one food at a time, it takes months, and the children who react at the lowest doses are often the ones least able to get through it.

The design was a multicentre, randomised, double-blind, placebo-controlled trial across ten centres in the United States, in around 180 participants, almost all of them children and adolescents. To enter, they had to be allergic to peanut and to at least two other foods such as cashew, milk or egg, and every one of those allergies was confirmed by a double-blind placebo-controlled food challenge at baseline. So this was a properly phenotyped, highly reactive population, not simply a sensitised one. They were randomised two to one to omalizumab or placebo, by subcutaneous injection dosed on weight and total IgE, for sixteen to twenty weeks, and then rechallenged. The primary endpoint was the proportion who could tolerate a single dose of at least 600 milligrams of peanut protein, roughly two or three peanuts, without dose-limiting symptoms.

The headline result was 67 per cent on omalizumab against 7 per cent on placebo. The key secondary endpoints went the same way: cashew 41 against 3 per cent, milk 66 against 10, and egg 67 against none. That consistency matters, because it suggests a genuine effect across allergens rather than something peculiar to peanut. Safety was reassuring, with injection-site reactions the main difference between the arms. On the strength of it, the FDA approved omalizumab for IgE-mediated food allergy in 2024.

The limitations I would flag are these. First, a third of the treated children still did not reach the threshold, and we cannot yet predict who they will be. Second, the endpoint is a supervised challenge, which is a surrogate for what families actually care about, which is what happens after an accidental exposure at a party. Third, sixteen to twenty weeks tells us nothing about durability or about what happens when the drug is stopped. And it is a biologic given long term, so there is a real cost and commissioning question the trial was never designed to answer.

Overall, I think it is genuinely practice-changing. It gives us, for the first time, a treatment that protects across several foods at once, and for patients too reactive for conventional immunotherapy it may be the only realistic option. What I would want answered next is how long the protection lasts, who responds, and whether it works best alone or as a bridge into oral immunotherapy. Thank you.

The strongest part of it is the design. It was properly randomised and the challenges were double-blind and placebo-controlled, which is hard to do well in food allergy, so I take the result seriously.

My main reservation is the population. These were children recruited through specialist centres with peanut allergy plus at least two other food allergies, so they are more severe than a lot of the patients I see, and I would be cautious about assuming the same effect size in a general clinic. The endpoint is the other thing I would flag. Tolerating 600 milligrams at a supervised challenge is a good measure for a trial, but what a family actually wants to know is whether their child is safer if they eat the wrong biscuit at a party, and this doesn't answer that directly.

It was also only sixteen to twenty weeks, so we don't know what happens when you stop, and there was no comparison against oral immunotherapy, which is the question I would most like answered. So I would say it establishes omalizumab as a real option, particularly for people too reactive for immunotherapy, but I would want durability and real-world data before I treated it as settled, and the cost question is still open.